Etiology and treatment of cough in idiopathic pulmonary fibrosis

Respiratory Medicine

Volumn 123, Issue , 2017, Pages 98-104

  Vigeland, Christine L ^a   Hughes, Andrew H ^a   Horton, Maureen R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cough; Gastroesophageal reflux disease; Idiopathic pulmonary fibrosis; Interferon ; Thalidomide

Indexed keywords

ANTITUSSIVE AGENT; BRADYKININ; CAPSAICIN; HISTAMINE; MUCIN 5B; NEUROPEPTIDE; TACHYKININ; ALPHA INTERFERON; THALIDOMIDE;

ASTHMA; CHRONIC COUGH; COMORBIDITY; COUGHING; DISEASE COURSE; DISEASE SEVERITY; ESOPHAGEAL PH MONITORING; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HUMAN; MUCOCILIARY CLEARANCE; MUCUS; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SENSORY NERVE CELL; COMPLICATION;

ANTITUSSIVE AGENTS; COMORBIDITY; COUGH; GASTROESOPHAGEAL REFLUX; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERFERON-ALPHA; QUALITY OF LIFE; THALIDOMIDE;

EID: 85007417163     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.12.016     Document Type: Review

References (80)

1. [1] Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.F., Flaherty, K.R., Lasky, J.A., Lynch, D.A., Ryu, J.H., Swigris, J.J., Wells, A.U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D.M., Johkoh, T., Kim, D.S., King, T.E. Jr., Kondoh, Y., Myers, J., Muller, N.L., Nicholson, A.G., Richeldi, L., Selman, M., Dudden, R.F., Griss, B.S., Protzko, S.L., Schunemann, H.J., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183:6 (2011), 788–824.
2. [2] Coultas, D.B., Zumwalt, R.E., Black, W.C., Sobonya, R.E., The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 150:4 (1994), 967–972.
3. [3] Bjoraker, J.A., Ryu, J.H., Edwin, M.K., Myers, J.L., Tazelaar, H.D., Schroeder, D.R., Offord, K.P., Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 157:1 (1998), 199–203.
4. [4] Daniil, Z.D., Gilchrist, F.C., Nicholson, A.G., Hansell, D.M., Harris, J., Colby, T.V., du Bois, R.M., A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 160:3 (1999), 899–905.
5. [5] Nicholson, A.G., Colby, T.V., du Bois, R.M., Hansell, D.M., Wells, A.U., the prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 162:6 (2000), 2213–2217.
6. [6] Douglas, W.W., Ryu, J.H., Schroeder, D.R., Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 161:4 Pt 1 (2000), 1172–1178.
7. [7] Ryerson, C.J., Abbritti, M., Ley, B., Elicker, B.M., Jones, K.D., Collard, H.R., Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 16:6 (2011), 969–975.
8. [8] Key, A.L., Holt, K., Hamilton, A., Smith, J.A., Earis, J.E., Objective cough frequency in idiopathic pulmonary fibrosis. Cough, 6, 2010, 4.
9. [9] Crystal, R.G., Fulmer, J.D., Roberts, W.C., Moss, M.L., Line, B.R., Reynolds, H.Y., Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann. Intern Med. 85:6 (1976), 769–788.
10. [10] Kilduff, C.E., Counter, M.J., Thomas, G.A., Harrison, N.K., Hope-Gill, B.D., Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study. Cough, 10, 2014, 4.
11. [11] Madison, J.M., Irwin, R.S., Chronic cough in adults with interstitial lung disease. Curr. Opin. Pulm. Med. 11:5 (2005), 412–416.
12. [12] Swigris, J.J., Kuschner, W.G., Jacobs, S.S., Wilson, S.R., Gould, M.K., Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 60:7 (2005), 588–594.
13. [13] Horton, M.R., Santopietro, V., Mathew, L., Horton, K.M., Polito, A.J., Liu, M.C., Danoff, S.K., Lechtzin, N., Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann. Intern Med. 157:6 (2012), 398–406.
14. [14] Lechtzin, N., Hilliard, M.E., Horton, M.R., Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. Chest 143:6 (2013), 1745–1749.
15. [15] Fox, A.J., Barnes, P.J., Urban, L., Dray, A., An in vitro study of the properties of single vagal afferents innervating Guinea-pig airways. J. Physiol. 469 (1993), 21–35.
16. [16] Mazzone, S.B., An overview of the sensory receptors regulating cough. Cough, 1, 2005, 2.
17. [17] Widdicombe, J., Functional morphology and physiology of pulmonary rapidly adapting receptors (RARs). Anat. Rec. A Discov. Mol. Cell Evol. Biol. 270:1 (2003), 2–10.
18. [18] Spina, D., McFadzean, I., Bertram, F.K., Page, C.P., Peripheral mechanisms II: the pharmacology of peripherally active antitussive drugs. Handb. Exp. Pharmacol.(187), 2009, 155–186.
19. [19] Canning, B.J., Mazzone, S.B., Meeker, S.N., Mori, N., Reynolds, S.M., Undem, B.J., Identification of the tracheal and laryngeal afferent neurones mediating cough in anaesthetized Guinea-pigs. J. Physiol. 557:Pt 2 (2004), 543–558.
20. [20] Canning, B.J., Anatomy and neurophysiology of the cough reflex: ACCP evidence-based clinical practice guidelines. Chest 129:1 Suppl (2006), 33S–47S.
21. [21] Ventresca, P.G., Nichol, G.M., Barnes, P.J., Chung, K.F., Inhaled furosemide inhibits cough induced by low chloride content solutions but not by capsaicin. Am. Rev. Respir. Dis. 142:1 (1990), 143–146.
22. [22] Choudry, N.B., Fuller, R.W., Pride, N.B., Sensitivity of the human cough reflex: effect of inflammatory mediators prostaglandin E2, bradykinin, and histamine. Am. Rev. Respir. Dis. 140:1 (1989), 137–141.
23. [23] Kroll, F., Karlsson, J.A., Lundberg, J.M., Persson, C.G., Capsaicin-induced bronchoconstriction and neuropeptide release in Guinea pig perfused lungs. J. Appl. Physiol. 68:4 (1990), 1679–1687 (1985).
24. [24] Martling, C.R., Saria, A., Fischer, J.A., Hokfelt, T., Lundberg, J.M., Calcitonin gene-related peptide and the lung: neuronal coexistence with substance P, release by capsaicin and vasodilatory effect. Regul. Pept. 20:2 (1988), 125–139.
25. [25] Saria, A., Martling, C.R., Yan, Z., Theodorsson-Norheim, E., Gamse, R., Lundberg, J.M., Release of multiple tachykinins from capsaicin-sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium, and vagal nerve stimulation. Am. Rev. Respir. Dis. 137:6 (1988), 1330–1335.
26. [26] Saria, A., Theodorsson-Norheim, E., Gamse, R., Lundberg, J.M., Release of substance P- and substance K-like immunoreactivities from the isolated perfused Guinea-pig lung. Eur. J. Pharmacol. 106:1 (1984), 207–208.
27. [27] Schuligoi, R., Peskar, B.A., Donnerer, J., Amann, R., Bradykinin-evoked sensitization of neuropeptide release from afferent neurons in the Guinea-pig lung. Br. J. Pharmacol. 125:2 (1998), 388–392.
28. [28] Emanueli, C., Grady, E.F., Madeddu, P., Figini, M., Bunnett, N.W., Parisi, D., Regoli, D., Geppetti, P., Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 31:6 (1998), 1299–1304.
29. [29] Shannon, R., Baekey, D.M., Morris, K.F., Nuding, S.C., Segers, L.S., Lindsey, B.G., Production of reflex cough by brainstem respiratory networks. Pulm. Pharmacol. Ther. 17:6 (2004), 369–376.
30. [30] Davis, J.B., Gray, J., Gunthorpe, M.J., Hatcher, J.P., Davey, P.T., Overend, P., Harries, M.H., Latcham, J., Clapham, C., Atkinson, K., Hughes, S.A., Rance, K., Grau, E., Harper, A.J., Pugh, P.L., Rogers, D.C., Bingham, S., Randall, A., Sheardown, S.A., Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405:6783 (2000), 183–187.
31. [31] Riccio, M.M., Myers, A.C., Undem, B.J., Immunomodulation of afferent neurons in Guinea-pig isolated airway. J. Physiol. 491:Pt 2 (1996), 499–509.
32. [32] Kamei, J., Takahashi, Y., Involvement of ionotropic purinergic receptors in the histamine-induced enhancement of the cough reflex sensitivity in Guinea pigs. Eur. J. Pharmacol. 547:1–3 (2006), 160–164.
33. [33] Myers, A.C., Kajekar, R., Undem, B.J., Allergic inflammation-induced neuropeptide production in rapidly adapting afferent nerves in Guinea pig airways. Am. J. Physiol. Lung Cell Mol. Physiol. 282:4 (2002), L775–L781.
34. [34] Mutoh, T., Bonham, A.C., Joad, J.P., Substance P in the nucleus of the solitary tract augments bronchopulmonary C fiber reflex output. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279:4 (2000), R1215–R1223.
35. [35] Mutoh, T., Bonham, A.C., Kott, K.S., Joad, J.P., Chronic exposure to sidestream tobacco smoke augments lung C-fiber responsiveness in young Guinea pigs. J. Appl. Physiol. 87:2 (1999), 757–768 (1985).
36. [36] Lee, P., Eccles, R., Cough induced by mechanical stimulation of the upper airway in humans. Acta Otolaryngol. 124:6 (2004), 720–725.
37. [37] Harrison, N.K., Idiopathic pulmonary fibrosis: a nervous cough?. Pulm. Pharmacol. Ther. 17:6 (2004), 347–350.
38. [38] Jones, R.M., Hilldrup, S., Hope-Gill, B.D., Eccles, R., Harrison, N.K., Mechanical induction of cough in idiopathic pulmonary fibrosis. Cough, 7, 2011, 2.
39. [39] Hope-Gill, B.D., Hilldrup, S., Davies, C., Newton, R.P., Harrison, N.K., A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:8 (2003), 995–1002.
40. [40] Doherty, M.J., Mister, R., Pearson, M.G., Calverley, P.M., Capsaicin induced cough in cryptogenic fibrosing alveolitis. Thorax 55:12 (2000), 1028–1032.
41. [41] Seibold, M.A., Smith, R.W., Urbanek, C., Groshong, S.D., Cosgrove, G.P., Brown, K.K., Schwarz, M.I., Schwartz, D.A., Reynolds, S.D., The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One, 8(3), 2013, e58658.
42. [42] Scholand, M.B., Wolff, R., Crossno, P.F., Sundar, K., Winegar, M., Whipple, S., Carey, P., Sunchild, N., Coon, H., Severity of cough in idiopathic pulmonary fibrosis is associated with MUC5 B genotype. Cough, 10, 2014, 3.
43. [43] McGarvey, L.P., Morice, A.H., Clinical cough and its mechanisms. Respir. Physiol. Neurobiol. 152:3 (2006), 363–371.
44. [44] Fahim, A., Dettmar, P.W., Morice, A.H., Hart, S.P., Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis: a Prospective Study, vol. 47, 2011, Medicina, Kaunas, 200–205 (4).
45. [45] Tobin, R.W., Pope, C.E. 2nd, Pellegrini, C.A., Emond, M.J., Sillery, J., Raghu, G., Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 158:6 (1998), 1804–1808.
46. [46] Raghu, G., Yang, S.T., Spada, C., Hayes, J., Pellegrini, C.A., Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 129:3 (2006), 794–800.
47. [47] Savarino, E., Carbone, R., Marabotto, E., Furnari, M., Sconfienza, L., Ghio, M., Zentilin, P., Savarino, V., Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur. Respir. J. 42:5 (2013), 1322–1331.
48. [48] Lee, J.S., Ryu, J.H., Elicker, B.M., Lydell, C.P., Jones, K.D., Wolters, P.J., King, T.E. Jr., Collard, H.R., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 184:12 (2011), 1390–1394.
49. [49] Sweet, M.P., Patti, M.G., Leard, L.E., Golden, J.A., Hays, S.R., Hoopes, C., Theodore, P.R., Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J. Thorac. Cardiovasc Surg. 133:4 (2007), 1078–1084.
50. [50] Bradford, W.Z., Brown, K.K., Noble, P.W., Starko, K.M., Schwartz, D.A., Raghu, G., Safrin, S., Weycker, D., Chronic use of anti-gastroesophageal reflux (GER) medications in patients with idiopathic pulmonary fibrosis (IPF). Chest, 126(4_MeetingAbstracts), 2004, 772S.
51. [51] Linden, P.A., Gilbert, R.J., Yeap, B.Y., Boyle, K., Deykin, A., Jaklitsch, M.T., Sugarbaker, D.J., Bueno, R., Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J. Thorac. Cardiovasc Surg. 131:2 (2006), 438–446.
52. [52] Ryan, N.M., Birring, S.S., Gibson, P.G., Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 380:9853 (2012), 1583–1589.
53. [53] Morice, A.H., Fontana, G.A., Belvisi, M.G., Birring, S.S., Chung, K.F., Dicpinigaitis, P.V., Kastelik, J.A., McGarvey, L.P., Smith, J.A., Tatar, M., Widdicombe, J., ERS guidelines on the assessment of cough. Eur. Respir. J. 29:6 (2007), 1256–1276.
54. [54] Jeyakumar, A., Brickman, T.M., Haben, M., Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. Laryngoscope 116:12 (2006), 2108–2112.
55. [55] Lim, K.G., Rank, M.A., Hahn, P.Y., Keogh, K.A., Morgenthaler, T.I., Olson, E.J., Long-term safety of nebulized lidocaine for adults with difficult-to-control chronic cough: a case series. Chest 143:4 (2013), 1060–1065.
56. [56] Abdulqawi, R., Dockry, R., Holt, K., Layton, G., McCarthy, B.G., Ford, A.P., Smith, J.A., P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385:9974 (2015), 1198–1205.
57. [57] Hodgson, D., Anderson, J., Reynolds, C., Oborne, J., Meakin, G., Bailey, H., Shaw, D., Mortimer, K., Harrison, T., The effects of azithromycin in treatment-resistant cough: a randomized, double-blind, placebo-controlled trial. Chest 149:4 (2016), 1052–1060.
58. [58] Yousaf, N., Monteiro, W., Parker, D., Matos, S., Birring, S., Pavord, I.D., Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial. Thorax 65:12 (2010), 1107–1110.
59. [59] Smith, S.M., Schroeder, K., Fahey, T., Over-the-counter (OTC) medications for acute cough in children and adults in community settings. Cochrane Database Syst. Rev., 11, 2014, CD001831.
60. [60] Bastian, R.W., Vaidya, A.M., Delsupehe, K.G., Sensory neuropathic cough: a common and treatable cause of chronic cough. Otolaryngol. Head. Neck Surg. 135:1 (2006), 17–21.
61. [61] Vertigan, A.E., Theodoros, D.G., Gibson, P.G., Winkworth, A.L., Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy. Thorax 61:12 (2006), 1065–1069.
62. [62] Ryan, N.M., Vertigan, A.E., Bone, S., Gibson, P.G., Cough reflex sensitivity improves with speech language pathology management of refractory chronic cough. Cough, 6, 2010, 5.
63. [63] Bowcock, S.J., Rassam, S.M., Ward, S.M., Turner, J.T., Laffan, M., Thromboembolism in patients on thalidomide for myeloma. Hematology 7:1 (2002), 51–53.
64. [64] Abdullah, H., Heaney, L.G., Cosby, S.L., McGarvey, L.P., Rhinovirus upregulates transient receptor potential channels in a human neuronal cell line: implications for respiratory virus-induced cough reflex sensitivity. Thorax 69:1 (2014), 46–54.
65. [65] Richeldi, L., du Bois, R.M., Raghu, G., Azuma, A., Brown, K.K., Costabel, U., Cottin, V., Flaherty, K.R., Hansell, D.M., Inoue, Y., Kim, D.S., Kolb, M., Nicholson, A.G., Noble, P.W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., Collard, H.R., Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370:22 (2014), 2071–2082.
66. [66] Okazaki, A., Ohkura, N., Fujimura, M., Katayama, N., Kasahara, K., Effects of pirfenidone on increased cough reflex sensitivity in Guinea pigs. Pulm. Pharmacol. Ther. 26:5 (2013), 603–608.
67. [67] Azuma, A., Taguchi, Y., Ogura, T., Ebina, M., Taniguchi, H., Kondoh, Y., Suga, M., Takahashi, H., Nakata, K., Sato, A., Kudoh, S., Nukiwa, T., Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir. Res., 12, 2011, 143.
68. [68] Woodcock, H.V., Molyneaux, P.L., Maher, T.M., Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des. Devel Ther. 7 (2013), 503–510.
69. [69] Taussig, H.B., The thalidomide syndrome. Sci. Am. 207 (1962), 29–35.
70. [70] D'Amato, R.J., Loughnan, M.S., Flynn, E., Folkman, J., Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 91:9 (1994), 4082–4085.
71. [71] Figg, W.D., Dahut, W., Duray, P., Hamilton, M., Tompkins, A., Steinberg, S.M., Jones, E., Premkumar, A., Linehan, W.M., Floeter, M.K., Chen, C.C., Dixon, S., Kohler, D.R., Kruger, E.A., Gubish, E., Pluda, J.M., Reed, E., A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 7:7 (2001), 1888–1893.
72. [72] Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J., Barlogie, B., Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341:21 (1999), 1565–1571.
73. [73] Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M.M., Pyle, L., Johnston, S.R., Ahern, R., Smith, I.E., Gore, M.E., Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer 82:4 (2000), 812–817.
74. [74] Figg, W.D., Arlen, P., Gulley, J., Fernandez, P., Noone, M., Fedenko, K., Hamilton, M., Parker, C., Kruger, E.A., Pluda, J., Dahut, W.L., A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin. Oncol. 28:4 Suppl 15 (2001), 62–66.
75. [75] Lazzerini, M., Martelossi, S., Magazzu, G., Pellegrino, S., Lucanto, M.C., Barabino, A., Calvi, A., Arrigo, S., Lionetti, P., Lorusso, M., Mangiantini, F., Fontana, M., Zuin, G., Palla, G., Maggiore, G., Bramuzzo, M., Pellegrin, M.C., Maschio, M., Villanacci, V., Manenti, S., Decorti, G., De Iudicibus, S., Paparazzo, R., Montico, M., Ventura, A., Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA 310:20 (2013), 2164–2173.
76. [76] Horton, M.R., Danoff, S.K., Lechtzin, N., Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax, 63(8), 2008, 749.
77. [77] Elias, L., Hoffman, R., Boswell, S., Tensen, L., Bonnem, E.M., A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results. Leukemia 1:2 (1987), 105–110.
78. [78] Lutherer, L.O., Nugent, K.M., Schoettle, B.W., Cummins, M.J., Raj, R., Birring, S.S., Jumper, C.A., Low-dose oral interferon alpha possibly retards the progression of idiopathic pulmonary fibrosis and alleviates associated cough in some patients. Thorax 66:5 (2011), 446–447.
79. [79] Allison, A.B., Goekjian, V.H., Potgieter, A.C., Wilson, W.C., Johnson, D.J., Mertens, P.P., Stallknecht, D.E., Detection of a novel reassortant epizootic hemorrhagic disease virus (EHDV) in the USA containing RNA segments derived from both exotic (EHDV-6) and endemic (EHDV-2) serotypes. J. Gen. Virol. 91:Pt 2 (2010), 430–439.
80. [80] Flaherty, K., Toews, G., Lynch, J.r., Kazerooni, E., Gross, B., Strawerman, R., Hariharan, K., Flint, A., Martinez, F., Steroids in idiopathic pulmonary fibrosis:a prospective assessment of adverse reactions, response to therapy and survival. Am. J. Med. 110:4 (2001), 278–282.